153 related articles for article (PubMed ID: 38311811)
21. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
22. Neo-adjuvant Vismodegib followed by radiation in locally advanced basal cell carcinoma.
Sabu DM; Kroes J; Gilham C; Fleming A; Kelleher FC
Curr Probl Cancer; 2021 Dec; 45(6):100736. PubMed ID: 33894989
[TBL] [Abstract][Full Text] [Related]
23. Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
Yurchenko AA; Pop OT; Ighilahriz M; Padioleau I; Rajabi F; Sharpe HJ; Poulalhon N; Dreno B; Khammari A; Delord M; Alberti A; Soufir N; Battistella M; Mourah S; Bouquet F; Savina A; Besse A; Mendez-Lopez M; Grange F; Monestier S; Mortier L; Meyer N; Dutriaux C; Robert C; Saiag P; Herms F; Lambert J; de Sauvage FJ; Dumaz N; Flatz L; Basset-Seguin N; Nikolaev SI
Clin Cancer Res; 2022 Apr; 28(7):1422-1432. PubMed ID: 35078858
[TBL] [Abstract][Full Text] [Related]
24. Expression profile of sonic hedgehog signaling-related molecules in basal cell carcinoma.
Kim HS; Kim YS; Lee C; Shin MS; Kim JW; Jang BG
PLoS One; 2019; 14(11):e0225511. PubMed ID: 31756206
[TBL] [Abstract][Full Text] [Related]
25. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.
Yang C; Yong L; Liang C; Li Y; Ma Y; Wei F; Jiang L; Zhou H; He G; Pan X; Hai B; Wu J; Xu Y; Liu Z; Liu X
Oncogene; 2020 Jun; 39(24):4711-4727. PubMed ID: 32404987
[TBL] [Abstract][Full Text] [Related]
26. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
28. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.
Sobanko JF; Okman J; Miller C
J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062
[TBL] [Abstract][Full Text] [Related]
29. Enhanced and Sustained Cutaneous Delivery of Vismodegib by Ablative Fractional Laser and Microemulsion Formulation.
Olesen UH; Clergeaud G; Hendel KK; Yeung K; Lerche CM; Andresen TL; Haedersdal M
J Invest Dermatol; 2020 Oct; 140(10):2051-2059. PubMed ID: 32135181
[TBL] [Abstract][Full Text] [Related]
30. Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology.
Juhasz ML; Marmur ES
J Drugs Dermatol; 2014 Jun; 13(6):729-33. PubMed ID: 24918565
[TBL] [Abstract][Full Text] [Related]
31. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
32. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
33. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
Von Hoff DD; LoRusso PM; Rudin CM; Reddy JC; Yauch RL; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Mackey HM; Lum BL; Darbonne WC; Marsters JC; de Sauvage FJ; Low JA
N Engl J Med; 2009 Sep; 361(12):1164-72. PubMed ID: 19726763
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
[TBL] [Abstract][Full Text] [Related]
36. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp.
Tauber G; Pavlovsky L; Fenig E; Hodak E
J Am Acad Dermatol; 2015 Nov; 73(5):799-801. PubMed ID: 26320385
[TBL] [Abstract][Full Text] [Related]
37. Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?
Zhu H; Lewis DJ
Expert Opin Pharmacother; 2022 Apr; 23(6):739-740. PubMed ID: 35258366
[TBL] [Abstract][Full Text] [Related]
38. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
[TBL] [Abstract][Full Text] [Related]
39. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
[TBL] [Abstract][Full Text] [Related]
40. Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.
Abidi A
Indian J Pharmacol; 2014; 46(1):3-12. PubMed ID: 24550577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]